The Camizestrant SERENA-6 trial shone at ASCO 2025, presented by Professor Nick Turner. This Phase 3 study targets ESR1-mutated, ER-positive,…
Browsing: ASCO
American Society of Clinical Oncology
Introduction to Post-CDK4/6 Inhibitor Treatment Treating hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (MBC) has improved with CDK4/6 inhibitors like…
The Matterhorn Trial, a landmark phase III study published in the New England Journal of Medicine, evaluates durvalumab, an anti-PD-L1…
FDA Voucher Program Oncology: Accelerated Approvals in Oncology On June 17, 2025, the FDA launched the Commissioner’s National Priority Voucher…
Welcome to this comprehensive web companion for the OncologyTube.com video, “HR+/HER2- metastatic breast cancer 2L outcomes: Top 10 from ASCO…
Welcome to this exclusive OncologyTube.com companion to our video, “Comprehensive Overview of Bispecific Antibodies in Cancer Therapy.” Bispecific antibodies (bsAbs)…
Introduction to HCC Treatment Insights Hepatocellular carcinoma (HCC) presents tough treatment challenges, requiring careful patient selection for local therapies. This…
The ASCO 2025 conference, held recently, shared new research that may shape cancer treatments. This article covers studies on treatment-induced…
Tarlatamab Phase 3 Results SCLC ASCO 2025 The tarlatamab phase 3 results for SCLC, shared at ASCO 2025, showed a…
Introduction to Pancreatic Cancer Treatment at ASCO 2025 At the ASCO 2025 Annual Meeting, Dr. Brian Wolpin presented groundbreaking updates…
At the 2025 ASCO Annual Meeting, new data on IO-based combinations in mRCC emerged. For instance, Dr. Brian Rini, MD…
This video presents the myeloma treatment algorithm 2025 for transplant-ineligible patients, shared by Dr. Vincent Rajkumar at ASCO 2025. Designed…
At the 2025 ASCO Annual Meeting, a phase 3 randomized trial revealed that the timing of immunotherapy in non-small cell…
What’s New at ASCO 2025? The ASCO 2025 conference in Chicago brought exciting news for cancer care. A major study,…
ATOMIC Trial ASCO 2025: Key Results RevealedOn June 1, 2025, the ASCO Annual Meeting in Chicago presented the ATOMIC trial…
Introduction Cancer of Unknown Primary (CUP) diagnostics is a critical area for oncologists and researchers, as 2-5% of cancer cases…
Published: May 30, 2025 Pfizer shared results from the BRAFTOVI BREAKWATER trial at ASCO 2025. The trial tested BRAFTOVI® (encorafenib) with cetuximab…
Posted on May 30, 2025 by ASCO Editorial Team Artificial intelligence (AI) is reshaping the future of cancer research and…
The Top 10 GI Trials at ASCO 2025 are here (with Dates and Times), and OncologyTube proudly presents an exclusive…
OncologyTube.com presents the ASCO 2025 Top 10 Abstracts, highlighting practice-changing trials in oncology. It features advancements in cancer care, from…
The American Society of Clinical Oncology (ASCO) Annual Meeting is a pivotal event for oncology professionals, and ASCO 2025, happening…
The 2025 ASCO guidelines on sentinel lymph node biopsy (SLNB) for early-stage breast cancer are reshaping oncology care. Published in the Journal of Clinical Oncology, these recommendations, backed by extensive clinical trials, aim to reduce unnecessary procedures, lower costs, and address health disparities. Learn about the six key updates, their impact on patients, and how they promote personalized treatment while minimizing complications like lymphedema. Visit OncologyTube.com for more insights.